On 24 September, European regulators cleared the way for GW Pharma’s cannabinoid medicinal product to treat patients with two rare, severe forms of epilepsy. The European Commission approved Epidyolex to treat seizures associated with Lennox Gastaut syndrome (LGS) or Dravet
Continue Reading Navigating the Haze of Cannabis Rules and Regulations in Europe

On August 19, 2019, the National Credit Union Administration (“NCUA”) made an economically significant change to the hemp banking landscape.  As is the case with cannabis businesses generally, hemp operations have faced considerable limitations with respect to access to traditional
Continue Reading Credit Unions Lending to Hemp-Related Businesses is Permissible

We’ve written a lot about FDA’s current position on CBD in food and the ongoing process to evaluate a potential non-drug pathway for the ingredient that emerged seemingly out of nowhere to capture the attention of consumers, legislators, and regulators
Continue Reading NY and Ohio: Recent Legal Changes Diverge on Whether CBD Can Be Added to Food

On May 28, 2019, the United States Department of Agriculture’s (“USDA”) Office of the General Counsel issued a Legal Opinion, which attempts to address open questions relating to interstate transport of hemp. While the 2018 Farm Bill legalized hemp production,
Continue Reading USDA Legal Opinion Seeks To Clarify Interstate Transport of Hemp

FDA’s CBD Public Meeting featured a full house of manufacturers, researchers, health professionals, trade association representatives, and other stakeholders.  Each speaker was given a few minutes to offer their input in response to FDA’s call for submissions relating to health
Continue Reading FDA CBD Public Meeting Features Overwhelming Calls For Robust Regulation and Enforcement; Relaxation of Obstacles to Research